NTLA Q2 EPS Increased by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised its Q2 2026 EPS estimate for Intellia to ($0.75) from ($0.84) and projects a dramatic turnaround with FY2027–FY2030 EPS forecasts of $12.98, $14.82, $40.30 and $68.47 respectively, while consensus FY2026 remains negative at ($3.50).
• Intellia beat Q4 expectations, reporting ($0.83) EPS versus a ($0.99) consensus and revenue of $23.02M (up 78.4% y/y vs est $12.17M), yet the stock carries a MarketBeat consensus rating of Hold with mixed analyst price targets (~$20.09) and high institutional ownership (88.77%).

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for Intellia Therapeutics in a report released on Wednesday, April 29th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.75) per share for the quarter, up from their previous estimate of ($0.84). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.50) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics' Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at $12.98 EPS, FY2028 earnings at $14.82 EPS, FY2029 earnings at $40.30 EPS and FY2030 earnings at $68.47 EPS.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. During the same quarter in the prior year, the business posted ($1.27) EPS. The firm's revenue was up 78.4% compared to the same quarter last year.

A number of other research firms have also weighed in on NTLA. The Goldman Sachs Group raised their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the company a "sell" rating in a report on Tuesday, April 28th. Royal Bank Of Canada increased their price target on Intellia Therapeutics from $9.00 to $15.00 and gave the company a "sector perform" rating in a research report on Tuesday, March 3rd. HC Wainwright raised their price objective on Intellia Therapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. JonesTrading raised shares of Intellia Therapeutics from a "hold" rating to a "buy" rating and set a $29.00 price objective on the stock in a report on Wednesday, March 4th. Finally, Chardan Capital upped their target price on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $20.09.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $13.26 on Monday. The stock has a 50 day moving average price of $13.62 and a two-hundred day moving average price of $12.65. The firm has a market capitalization of $1.57 billion, a P/E ratio of -3.46 and a beta of 1.93. Intellia Therapeutics has a 52 week low of $6.83 and a 52 week high of $28.25.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the business. Contrarius Group Holdings Ltd boosted its holdings in shares of Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company's stock worth $101,719,000 after buying an additional 4,337,428 shares during the last quarter. ARK Investment Management LLC raised its position in Intellia Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company's stock worth $127,724,000 after acquiring an additional 2,288,146 shares during the period. Vanguard Group Inc. raised its position in Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company's stock worth $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp boosted its stake in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company's stock valued at $57,705,000 after acquiring an additional 1,447,967 shares during the last quarter. Finally, Jupiter Asset Management Ltd. purchased a new position in Intellia Therapeutics in the third quarter valued at about $23,519,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.